SCHEMBL9890719

SCHEMBL9890719

CCNC(=O)Cc1ccccc1-c1ccccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.49
HTT P42858 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 4/20 0.47
RAB9A P51151 3/20 0.47
ALDH1A1 P00352 3/20 0.47
APAF1 O14727 1/20 0.47
TDP2 O95551 1/20 0.47
NSD2 O96028 1/20 0.47
MAPT P10636 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
SAE1 Q9UBE0 1/20 0.47
UBA2 Q9UBT2 1/20 0.47
DPP4 P27487 1/20 0.46
ERCC1 P07992 1/20 0.46
ERCC4 Q92889 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8441394 0.87 KMT2A (0.58) KMT2AHTTMEN1NPC1RAB9A
SCHEMBL9890718 0.84 KMT2A (0.49) KMT2AHTTMEN1NPC1RAB9A
SCHEMBL9890712 0.83 SMN1; SMN2 (0.47) KMT2AHTTMEN1NPC1RAB9A
SCHEMBL9890723 0.81 LMNA (0.47) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL2397254 0.78 KMT2A (0.45) KMT2AHTTMEN1ALDH1A1MAPT
SCHEMBL9890641 0.76 CXCL8 (0.57) RAB9AALDH1A1DPP4SMN1; SMN2
SCHEMBL9287839 0.75 DPP4 (0.63) KMT2ADPP4
SCHEMBL2394862 0.75 DPP4 (0.58) KMT2ANPC1RAB9AALDH1A1APAF1
SCHEMBL3860837 0.75 AKR1B1 (0.57) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL29859740 0.75 AKR1B1 (0.52) KMT2AMEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KMT2A 78/4885HTT 3070/4885MEN1 1467/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KMT2A 78/4885HTT 3070/4885MEN1 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.